GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...

GSK plc (LON:GSK – Get Free Report) insider Jonathan Symonds bought 7,150 shares of the stock in a transaction dated ...

Shares of GSK PLC GSK dropped 1.59% to £13.92 Tuesday, on what proved to be an all-around poor trading session for the stock ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50 ... corporate insider sentiment is positive on ...

GSK plc GSK reported third-quarter 2024 core ... The upside was partially offset by the removal of the Average Manufacturer Price cap on Medicaid drug prices in the United States, adversely ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales ...

In a report released today, Jo Walton from UBS maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...